ZBIO

Zenas BioPharma, Inc. (ZBIO) Business Model Analysis (2026)

Invetso Score: 2/10 — Weak · Last Updated: 2026-08-01

Overall Score

Revenue Model

Revenue per share remains extremely low at 0.0158 TTM, indicating a very small commercial base.

Price-to-sales is 1972.9x, implying the market is pricing in substantial future growth despite minimal current revenue.

Profitability

Gross margin is deeply negative at -59.7% TTM, showing core operations are not yet profitable.

Operating and net margins remain severely negative at -475.6% and -484.4% TTM, respectively.

Cash Generation

Free cash flow remains negative on a per-share basis at -3.58 TTM, despite a reported free cash flow to equity figure of 70.2M.

Operating cash flow is negative at -3.43 TTM, indicating the business is still consuming cash from operations.

Balance Sheet Strength

Liquidity is strong with a current ratio of 9.93x and cash ratio of 2.99x, providing a sizable near-term cushion.

Debt appears manageable relative to market value, with debt-to-market-cap at 11.3% and net debt to EBITDA near zero.

Capital Efficiency

Returns on capital remain deeply negative, with ROIC at -74.7% and ROE at -189.7% TTM.

Asset turnover is extremely low at 0.0014x, suggesting the asset base is not being converted into revenue efficiently.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Zenas BioPharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →